Dr. Kewalramani will join the Board of Directors for Ginkgo Bioworks, Inc. after she has been recognized for her work in innovating the pharmaceutical industry.
Dr. Kewalramani speaks on the difficulties for her first days as CEO of Vertex in the middle of a global pandemis, as well as her plans for the company's success in the future.
Dr. Kewalramani was recognized by The International Institute of New England with Golden Door Award for her achievements as the President and CEO of Vertex.
Reshma Kewalramani, CEO and President of Vertex Pharmaceuticals is profiled in honour of her 2020 Boston Business Journal Woman Who Mean Business award.
Reshma Kewalramani, MD, was honored for her work at Vertex Pharmaceuticals, notably the research and development for a drug that represents a "functional cure for about 90% of patients diagnosed with cystic fibrosis." She aims to lead Vertex in transforming or curing two, three, or four more diseases in the next decade. "I would love to do what we’ve done in cystic fibrosis multiple times, and I see that as entirely possible,” Kewalramani says.
